ROSEN, GLOBAL INVESTOR COUNSEL, Continues To Investigate Securities Claims Against Sonoma Pharmaceuticals, Inc. - SNOA
Rosen Law Firm is investigating potential securities claims on behalf of Sonoma Pharmaceuticals shareholders due to allegations of materially misleading business information. Following Sonoma's filing of a Form 8-K on November 17, 2020, which stated that its financial statements for the quarter ending June 30, 2020, contained significant errors and needed to be restated, the company's stock fell over 14%. Rosen Law Firm is preparing a securities lawsuit for affected investors, urging them to join the action.
- None.
- Sonoma's stock fell over 14% after the announcement of significant financial statement errors.
- The company is facing a lawsuit due to allegations of misleading information.
NEW YORK, Jan. 18, 2021 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA) resulting from allegations that Sonoma may have issued materially misleading business information to the investing public.
On November 17, 2020, after market hours, Sonoma filed a Form 8-K with the U.S. Securities and Exchange Commission announcing that Sonoma's "unaudited condensed consolidated interim financial statements for the quarter ended June 30, 2020 should no longer be relied upon." Sonoma continued that the financial statements for this time period "contained material errors" and that "the Company will need to restate them."
On this news, Sonoma's share price fell
Rosen Law Firm is preparing a securities lawsuit on behalf of Sonoma shareholders. If you purchased securities of Sonoma please visit the firm's website at http://www.rosenlegal.com/cases-register-1992.html to join the securities action. You may also contact Phillip Kim of Rosen Law Firm toll free at 866-767-3653 or via email at mailto:pkim@rosenlegal.com or cases@rosenlegal.com.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 3 each year since 2013. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm's attorneys are ranked and recognized by numerous independent and respected sources. Rosen Law Firm has secured hundreds of millions of dollars for investors.
Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/rosen-global-investor-counsel-continues-to-investigate-securities-claims-against-sonoma-pharmaceuticals-inc--snoa-301210408.html
SOURCE Rosen Law Firm, P.A.
FAQ
What allegations is Sonoma Pharmaceuticals facing?
How did Sonoma's stock perform after the financial errors announcement?
What is the stock symbol for Sonoma Pharmaceuticals?
What is Rosen Law Firm's role regarding Sonoma Pharmaceuticals?
When did Sonoma Pharmaceuticals disclose the need to restate its financials?
